AI Article Synopsis
- - The study aimed to evaluate how effective Lu-labeled peptide receptor radionuclide therapy (PRRT) is for patients with metastatic neuroendocrine tumors that cannot be surgically removed.
- - Researchers analyzed data from 18 studies involving 1,920 patients and found that the disease response rates were around 29.1% to 30.6%, while disease control rates were between 74.1% and 81.1% depending on the criteria used.
- - The findings suggest that Lu PRRT, typically involving four treatment sessions, is a promising approach for managing these challenging tumors, showing significant effectiveness in controlling disease progression.
Article Abstract
Objective: The purpose of this study was to assess the efficacy of Lu-labeled peptide receptor radionuclide therapy (PRRT) induction treatments for patients with unresectable metastatic neuroendocrine tumors.
Methods: MEDLINE, EMBASE, and Ovid were systematically searched with keywords "lutetium," "Lu-177," "PRRT," "neuroendocrine," and "prognosis." Studies evaluating treatment with Lu-labeled PRRT were assessed for disease response and/or disease control rate by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 or 1.1, modified RECIST, Southwest Oncology Group (SWOG), or modified SWOG criteria. Pooled proportions of disease response and control rates were calculated for both fixed- and random-effects models.
Results: Eighteen studies with 1920 patients were included (11 with 1268 patients using RECIST and 6 with 804 patients using SWOG). By RECIST criteria, the pooled disease response rate by random-effects model was 29.1% (95% confidence interval [CI], 20.2%-38.9%), and disease control rate was 74.1% (95% CI, 67.8%-80.0%). By SWOG criteria, the pooled disease response rate by random-effects model was 30.6% (95% CI, 20.7%-41.5%), and disease control rate was 81.1% (95% CI, 76.4%-85.4%).
Conclusions: Induction therapy, typically 4 treatments, with Lu PRRT is an effective method of treating unresectable metastatic neuroendocrine tumors with significant disease response and control rates.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000002646 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Expression characteristics of in citrus and analysis of its interacting protein.
Plant Signal Behav
December 2025
School of Medical Technology, Chongqing Three Gorges Medical College, Chongqing, China.
The most damaging disease affecting citrus globally is Huanglongbing (HLB), primarily attributed to the infection by ' asiaticus' (Las). Based on comparative transcriptome data, two cellulose synthase (CESA) genes responsive to Las infection induction were screened, and one gene cloned with higher differential expression level was selected and named . we verified the interaction between CsCESA1 and citrus exopolysaccharide 2 (CsEPS2) proteins.
View Article and Find Full Text PDF[Quick decisionmaking for acute pulmonary embolism patients].
Ned Tijdschr Geneeskd
December 2024
Leids Universitair Medisch Centrum, Leiden. Afd. Trombose & Hemostase.
Treatment options for patients with severe pulmonary embolism (PE) have increased substantially over the past decade. Although systemic thrombolysis is still the reperfusion therapy of choice for hemodynamically unstable PE patients, several new catheter guided reperfusion therapies have emerged as possibly safer alternatives. These therapies are increasingly implemented in clinical practice even though their efficacy and safety are yet to be proven by clinical outcome studies.
View Article and Find Full Text PDFClinical Practice Guidelines for the Management of Congenital Syphilis in Japan, 2023: Executive Summary.
Pediatr Infect Dis J
December 2024
From the Japanese Society for Pediatric Infectious Diseases.
Congenital syphilis (CS) is a mother-to-child infection caused by the bacterium Treponema pallidum, transmitted through the placenta. In Japan, the number of syphilis cases has recently increased, accompanied by an increase in CS cases. Thus, automated methods for serum antibodies with serial values, without a 2× dilution sequence, have been widely used.
View Article and Find Full Text PDFHigh Interleukin (IL)-6 is Associated with Lower Lung Function and Increased Likelihood of Metabolic Dysfunction in Asthma.
Pulm Ther
December 2024
Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
Introduction: Asthma is a complex condition characterized by airway inflammation. Interleukin-6 (IL-6) plays a significant role in asthma pathogenesis through its effects on T cells and its association with pro-inflammatory responses. Both lung and circulating IL-6 levels are elevated in asthma.
View Article and Find Full Text PDFRASGEF1C as a novel prognostic biomarker for LUAD.
Discov Oncol
December 2024
Department of Thoracic Surgery, Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, No. 1500 Zhouyuan Road, Pudong New Area, Shanghai, China.
Lung adenocarcinoma (LUAD) is a common histologic lung cancer with high morbidity and mortality, and most patients have distant metastases at diagnosis. RasGEF Domain Family Member 1C (RASGEF1C) could regulated Alzheimer's disease. However, its function in various cancers, including LUAD, is poorly understood.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!